Welcome to our dedicated page for Movano SEC filings (Ticker: MOVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the path from prototype to FDA clearance can feel overwhelming when Movano Inc.’s disclosures stretch over hundreds of pages of technical jargon. Whether you’re watching the Evie Ring’s clinical milestones or simply need R&D burn-rate figures, Stock Titan’s AI turns dense paragraphs into clear takeaways, making Movano Inc. SEC filings explained simply a reality.
Need the details fast? Our dashboard streams every document the moment it lands on EDGAR—from a Movano Inc. quarterly earnings report 10-Q filing that breaks down sensor R&D costs, to an Movano Inc. 8-K material events explained summary covering fresh trial data. Curious about leadership confidence? We surface Movano Inc. insider trading Form 4 transactions and send real-time alerts for each Movano Inc. Form 4 insider transactions real-time update. Want the big picture without wading through footnotes? Click the AI summary beside any Movano Inc. annual report 10-K simplified or drill into the Movano Inc. proxy statement executive compensation tables in seconds.
Professionals use these insights to:
- Compare cash runway across quarters with Movano Inc. earnings report filing analysis
- Monitor FDA-related milestones disclosed in 8-Ks
- Spot patterns in Movano Inc. executive stock transactions Form 4 ahead of clinical announcements
Movano Inc. is soliciting proxies for its September 26, 2025 annual meeting to vote on four proposals: election of two Class I directors (Emily Wang Fairbairn and Michael Leabman), approval of an amendment to effect a board-determined reverse stock split at a ratio between 1-for-2 and 1-for-15, approval to increase authorized common shares from 500,000,000 to 2,000,000,000, and ratification of the Audit Committee’s selection of RBSM LLP as independent auditors for fiscal 2025. The Board recommends voting FOR all proposals. The company disclosed it received a Nasdaq notice for failure to maintain a minimum $1.00 bid price and for a late Form 10-Q filing and has appealed the delisting determination; the reverse split proposal is presented as a remedy. The proxy materials include director biographies, committee charters, compensation practices and employment arrangements. The filing contains placeholders where the exact number of shares outstanding and certain record-date ownership figures should appear.